

Tania Jain

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/887518/tania-jain-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98
papers

906
citations

18
h-index

27
g-index

123
ext. papers

1,431
ext. citations

3.8
avg, IF

4.53
L-index

#	Paper	IF	Citations
98	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.. <i>Nature Medicine</i> , 2022 ,	50.5	13
97	Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.. <i>Leukemia and Lymphoma</i> , 2022 , 1-7	1.9	2
96	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics.. <i>Transplantation Direct</i> , 2022 , 8, e1268	2.3	3
95	Insights into the Pathobiology of Secondary AML. <i>Hematologic Malignancies</i> , 2021 , 57-68	0	
94	The Presence of SETBP1, RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents. <i>Blood</i> , 2021 , 138, 1520-1520	2.2	
93	The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies. <i>Blood</i> , 2021 , 138, 253-253	2.2	0
92	Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab. <i>Blood</i> , 2021 , 138, 1846-1846	2.2	
91	Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofaa598	1	13
90	Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
89	Accelerated and Blast Phase Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 325-335	3.1	2
88	Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. <i>British Journal of Haematology</i> , 2021 , 195, 660-668	4.5	6
87	Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. <i>British Journal of Haematology</i> , 2021 , 193, 1142-1150	4.5	5
86	Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms. <i>EJHaem</i> , 2021 , 2, 607-615	0.9	1
85	Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?. <i>Leukemia and Lymphoma</i> , 2021 , 62, 252-254	1.9	1
84	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 6-20		12
83	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 921.e1-921.e10		2
82	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. <i>Blood Advances</i> , 2021 , 5, 3397-3406	7.8	7

81	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 642-649		4
80	Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 909.e1-909.e6		0
79	American Society for Transplantation and Cellular Therapy Guidelines for Fellowship Training in Hematopoietic Cell Transplantation and Immune Effector Cell Therapy.. <i>Transplantation and Cellular Therapy</i> , 2021 ,		1
78	Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. <i>American Journal of Transplantation</i> , 2020 , 20, 2254-2259	8.7	33
77	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020 , 4, 1965-1973	7.3	23
76	Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity. <i>Leukemia</i> , 2020 , 34, 3060-3063	10.7	3
75	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Blood Cancer Journal</i> , 2020 , 10, 36	7	6
74	Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. <i>Hematological Oncology</i> , 2020 , 38, 654-664	1.3	2
73	Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1071-1076	4.7	32
72	Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020 , 11, 2040620719899897	5.7	16
71	Immunophenotypic and molecular analysis of a B cell lymphoma with discordant light chain expression at different anatomic sites. <i>Journal of Hematopathology</i> , 2020 , 13, 117-123	0.4	0
70	Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use. <i>Blood</i> , 2020 , 136, 44-45	2.2	
69	Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL. <i>Blood</i> , 2020 , 136, 42-44	2.2	
68	Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN). <i>Blood</i> , 2020 , 136, 40-40	2.2	
67	Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. <i>Blood</i> , 2020 , 136, 33-34	2.2	3
66	Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6656-6667	15.9	55
65	Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1248-1269	7.3	10
64	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , 4, 3180-3190	7.8	4

63	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. <i>Blood Advances</i> , 2020 , 4, 3776-3787	7.8	59
62	Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e263-e264	4.7	
61	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2020 , 4, 5078-5088	7.8	6
60	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020 , 4, 676-686	7.8	51
59	Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1996-2002	1.9	6
58	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2305-2321	4.7	68
57	HHV-8-Associated Lymphoproliferative Disorders and Pathogenesis in an HIV-Positive Patient. <i>Case Reports in Hematology</i> , 2019 , 2019, 4536157	0.7	6
56	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2019 , 33, 2540-2544	10.7	20
55	Cytomegalovirus Reactivation Promotes CD8+ T Cell Subset Recovery after Unmodified Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, S326-S327	4.7	2
54	Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis. <i>BMJ Supportive and Palliative Care</i> , 2019 , 9, 425-433	2.2	11
53	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2019 , 54, 204-211	4.4	27
52	Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019 , 60, 110-117	1.9	5
51	Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells. <i>Blood</i> , 2019 , 134, 1947-1947	2.2	2
50	An Online Mindfulness-Based Cognitive Behavioral Therapy Intervention for Youth Diagnosed With Major Depressive Disorders: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2019 , 8, e11591	2	1
49	Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T). <i>Blood</i> , 2019 , 134, 4455-4455	2.2	
48	Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management. <i>Blood</i> , 2019 , 134, 4458-4458	2.2	
47	Monoclonal antibody utilization characteristics in patients with multiple myeloma. <i>Anti-Cancer Drugs</i> , 2019 , 30, 859-865	2.4	2
46	Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 728-733	4.7	16

45	Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2034-2041	1.9	
44	High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 239-247	4.7	19
43	Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 398-402	4.7	5
42	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. <i>Annals of Hematology</i> , 2018 , 97, 1453-1462	3	18
41	High Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, S48	4.7	2
40	Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2018 , 93, 1220-1226	7.1	6
39	Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 486-492.e1	2	3
38	The effect of neutropenic diets on infection and mortality rates in cancer patients: An updated systematic review and meta- analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e22087-e22087	2.2	
37	Rituximab maintenance for mantle cell lymphoma: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e19557-e19557	2.2	
36	Choosing a reduced intensity conditioning, fludarabine melphalan versus fludarabine busulfan: A meta-analysis and systematic review.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e19017-e19017	2.2	
35	Does Early T Cell Chimerism Predict Outcomes after Allogeneic Hematopoietic Cell Transplantation ?. <i>Blood</i> , 2018 , 132, 3360-3360	2.2	
34	Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score. <i>Blood</i> , 2018 , 132, 4288-4288	2.2	
33	Results of a Flow Cytometry Assay Measuring Oxidative Stress Relief As a Predictor of Immunomodulatory Drugs (IMiDs) Sensitivity in Myeloma. <i>Blood</i> , 2018 , 132, 4443-4443	2.2	
32	Clinical Outcomes of Matched Unrelated Allogeneic Stem Cell Transplant Patients: Low Dose ATG Vs. No ATG. <i>Blood</i> , 2018 , 132, 5715-5715	2.2	
31	No free rides: management of toxicities of novel immunotherapies in ALL, including financial. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 25-34	3.1	13
30	No free rides: management of toxicities of novel immunotherapies in ALL, including financial. <i>Blood Advances</i> , 2018 , 2, 3393-3403	7.8	34
29	Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. <i>Leukemia Research</i> , 2017 , 54, 73-77	2.7	21
28	Allogeneic Stem Cell Transplantation in Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1429-1436	4.7	20

27	Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, S279-S280	4.7	2
26	Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2017 , 7, 642	7	14
25	Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics. <i>Blood</i> , 2017 , 130, 864-864	2.2	2
24	Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 157-63	4.7	48
23	Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2016 , 91, E504-E505	7.1	5
22	Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab. <i>Annals of Hematology</i> , 2016 , 95, 1323-7	3	13
21	Bronchoscopy can be done safely in patients with thrombocytopenia. <i>Transfusion</i> , 2016 , 56, 344-8	2.9	22
20	Bone Disease in Myeloma: The Claws of CRAB. <i>Clinical Cancer Research</i> , 2016 , 22, 1301-3	12.9	1
19	Reversible Cardiotoxicity Associated with Carfilzomib Use in Patients with Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2126-2126	2.2	3
18	Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis. <i>Blood</i> , 2016 , 128, 4653-4653	2.2	
17	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016 , 128, 1810-1810	2.2	
16	Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients. <i>Blood</i> , 2016 , 128, 3452-3452	2.2	
15	Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL). <i>Blood</i> , 2016 , 128, 4629-4629	2.2	
14	The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 1101-1108	3.5	7
13	BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 531-5	2	11
12	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias. <i>Blood</i> , 2015 , 126, 1361-1361	2.2	2
11	Pegylated Interferon Alpha-2a in 75 Patients with Myeloproliferative Neoplasms: A Single Center Experience. <i>Blood</i> , 2015 , 126, 2818-2818	2.2	2
10	Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma. <i>Cureus</i> , 2015 , 7, e410	1.2	6

9	Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant. <i>Journal of Clinical Apheresis</i> , 2014 , 29, 293-8	3.2	3
8	Clinicopathologic features of patients with KRAS wild-type pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 192-192	2.2	1
7	Severe Thrombocytopenia Does Not Increase Bleeding Complications in Patients Undergoing Bronchoscopy. <i>Blood</i> , 2014 , 124, 4293-4293	2.2	
6	Schnitzler syndrome: an under-diagnosed clinical entity. <i>Haematologica</i> , 2013 , 98, 1581-5	6.6	28
5	Prospective Evaluation Of Risk Factors For Clostridium Difficile Colonization Among Allogenic Hematopoietic Stem Cell Transplant Recipients, 2010-2012. <i>Blood</i> , 2013 , 122, 4563-4563	2.2	3
4	Characteristics of colorectal cancer in patients younger than 40 years compared to older patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 371-371	2.2	1
3	Levamisole-induced leukocytoclastic vasculitis and neutropenia in a patient with cocaine use: an extensive case with necrosis of skin, soft tissue, and cartilage. <i>Addiction Science & Clinical Practice</i> , 2012 , 7, 19	4.1	39
2	Successful Hematopoietic Stem Cells (HSC) Mobilization in Patients Who Fail Plerixafor Mobilization for Autologous Stem Cells Transplant (ASCT). <i>Blood</i> , 2012 , 120, 1913-1913	2.2	
1	CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias. <i>EJHaem</i> , 3 , 32	0.9	2